CN117942367A - Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury - Google Patents

Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury Download PDF

Info

Publication number
CN117942367A
CN117942367A CN202311772251.7A CN202311772251A CN117942367A CN 117942367 A CN117942367 A CN 117942367A CN 202311772251 A CN202311772251 A CN 202311772251A CN 117942367 A CN117942367 A CN 117942367A
Authority
CN
China
Prior art keywords
preparation
parts
water
pinocembrin
ischemic injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311772251.7A
Other languages
Chinese (zh)
Inventor
于永鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Hospital of Traditional Chinese Medicine
Original Assignee
Qingdao Hospital of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Hospital of Traditional Chinese Medicine filed Critical Qingdao Hospital of Traditional Chinese Medicine
Priority to CN202311772251.7A priority Critical patent/CN117942367A/en
Publication of CN117942367A publication Critical patent/CN117942367A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the technical field of application of pinocembrin, and discloses application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, wherein 10 parts of pinocembrin, 6 parts of salvianic acid A, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach kernel, 7 parts of chrysanthemum, 6 parts of poria cocos, 4 parts of achyranthes and 3 parts of bitter orange are weighed according to parts by weight; mixing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, semen Persicae, flos Chrysanthemi, poria, achyranthis radix, fructus Aurantii, pulverizing into powder, and mixing with pinocembrin and tanshinol to obtain preparation for preventing cerebral ischemic injury. The pinocembrin prepared by the preparation method of pinocembrin has high purity, so that the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.

Description

Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury
Technical Field
The invention belongs to the technical field of application of pinocembrin, and particularly relates to application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury.
Background
The cerebrovascular diseases have the characteristics of high disability rate, high death rate and high recurrence rate, the severe omeiensis threatens the life health and the life quality of human beings, the cerebrovascular diseases occupy the first place of death causes of urban and rural residents in China, account for 22.45 percent of the total death number, and are diseases with single diseases and highest disability rate, thus becoming serious public health problems. In China, cerebral infarction accounts for about 70% of cerebrovascular diseases, the medical cost for treating the cerebrovascular diseases per year is up to 1400 hundred million yuan, and the cerebral infarction brings heavy burden to families and society. Therefore, importance is attached to the prevention and treatment of cerebral infarction, and the method has extremely important significance for the whole society. A series of pathophysiological lesions are caused after acute cerebral ischemia: stopping synthesis of neuron protein, depolarizing, increasing calcium ion inflow, releasing excitatory amino acid in large quantity, etc., resulting in overload of intracellular calcium, increased generation of oxygen free radical, change of mitochondrial function, inducing apoptosis of neuron, etc. At present, in the research of medicines for treating cerebral ischemia, two strategies are mainly based, namely, the development of neuroprotectants aiming at protecting nerve cell functions aims at protecting and recovering nerve functions in ischemic areas by blocking cascade reactions of nerve cell death through medicines; secondly, it is desirable to restore blood supply to the ischemic area of the brain by revascularization, dilation or revascularization. The medicine for improving blood supply is more commonly used in clinic at present: for example r-tPA, which has excellent thrombolytic effect, but this drug application has strict time window limitations, and early ischemic stroke blood brain barrier disruption is an important pathophysiological basis leading to ischemia reperfusion injury, angiogenic cerebral edema and hemorrhagic transformation. The neuroprotectant is based on the intervention of cytopathology biochemical cascade, and can reduce ischemic brain injury by reducing intracellular calcium overload, antagonizing excitatory amino acid toxicity, scavenging oxygen free radicals, inhibiting inflammatory reaction and other ways, and promote the recovery of nerve function. Although NMDA receptor antagonists may block NMDA receptor mediated neuronal death or apoptosis, inhibiting neuronal excitotoxicity. NMDA receptor antagonists, however, do not perform well in clinical trials because, when administered to patients with acute cerebral ischemia, higher doses tend to cause hypertension, dysmnesia and even conversely neurotoxicity to accelerate patient death: however, too low a dose does not provide neuroprotection, and the above drawbacks limit the use of NMDA receptor antagonists as therapeutic agents for cerebral ischemia.
Studies show that pinocembrin can reduce nerve cell injury caused by oxygen glucose deprivation and has neuroprotective effect. The pinocembrin can antagonize intracellular calcium overload, reduce oxidative stress injury, nerve cell apoptosis and other links, and prevent ischemia reperfusion injury. The raw material pinocembrin adopted by the prior application of pinocembrin in preparation of preparations for preventing cerebral ischemic injury contains impurities, which influence the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury; meanwhile, in the preparation of the compound preparation, the quality of the adopted raw material salvianic acid A is poor, and the application quality of the pinocembrin in the preparation of the preparation for preventing cerebral ischemic injury is influenced.
Through the above analysis, the problems and defects existing in the prior art are as follows:
(1) The raw material pinocembrin adopted by the prior application of pinocembrin in preparation of preparations for preventing cerebral ischemic injury contains impurities, which influence the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury.
(2) The quality difference of the adopted raw material salvianic acid A affects the application quality of the pinocembrin in preparation of the preparation for preventing cerebral ischemic injury.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides an application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury.
The invention is realized in that the application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury is characterized by comprising the following steps:
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to parts by weight;
Soaking peach kernels in boiled water, and soaking for 1 to 2 hours with a small amount of edible salt; soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and oven drying at low temperature;
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii separately, and adjusting the pulverizing granularity;
and thirdly, mixing the processed peach kernels, red paeony root, szechuan lovage rhizome, chinese angelica, safflower, chrysanthemum, indian buead, twotooth achyranthes root, bitter orange, pinocembrin, danshensu and a newly added neuroprotectant to prepare the preparation for preventing cerebral ischemic injury.
Further, the low-temperature drying removes moisture in the substance under the conditions of low temperature and reduced pressure:
Pumping air in the device by using a vacuum pump, creating a vacuum environment in the drying device, wherein water molecules in the substance are easier to evaporate due to the pressure reduction; in the whole process, a certain amount of heat is continuously supplied to the substance, and the heat is transmitted to the substance by radiation and convection from a heating system of the equipment; the moisture will change from liquid to gas after obtaining enough heat and then be separated from the substance; the separated water vapor is pumped by a vacuum pump.
Further, the preparation method of the pinocembrin comprises the following steps:
(1) Extracting propolis with purified water and edible alcohol at different ratio, separating solid from liquid, mixing filtrates, and regulating the content of effective components to standard requirement to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
(2) Adding 96% ethanol to the concentrated solution until the ethanol content is about 75%, standing overnight, collecting supernatant, and concentrating to obtain extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
(3) Semi-preparative high performance liquid chromatography separation and purification of samples: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
Further, the heat extraction time was 3 hours.
Further, the number of extraction times was 7.
Further, the distilled water is used in an amount of 11 times during the heating extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
Further, the preparation method of the tanshinol comprises the following steps:
1) Slicing Saviae Miltiorrhizae radix, and extracting with alkaline water solution with pH of 7 at 86 deg.C to obtain extract containing salvianic acid A; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
2) Loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
Further, the alkaline water used for the extraction is sodium hydroxide, potassium hydroxide or ammonia water.
Further, the extraction times of the hot dipping method are 5 times, the dosage of alkaline water is 17 times of the weight of the red sage root medicine, and the extraction time of each time is 3 hours.
Further, the acid is hydrochloric acid, acetic acid or sulfuric acid.
Further, the ethanol is absolute ethanol or 95% ethanol.
In combination with the technical scheme and the technical problems to be solved, the technical scheme to be protected has the following advantages and positive effects:
First, the present invention has increased the neuroprotective agent phosphatidylcholine, a substance that has been shown to protect nerve cells, reduce oxidative stress, and improve nerve cell function, thereby enhancing the prophylactic effect of the agent on ischemic brain injury. Secondly, by separately crushing each raw material, the property of each medicine can be expressed under the optimal granularity, which is beneficial to the efficacy exertion of the medicine. Finally, by changing the treatment method of the peach kernel, low-temperature drying is used for replacing high-pressure cooking, active ingredients of the peach kernel can be better preserved, and the overall effect of the medicament is improved.
Secondly, the purity of the pinocembrin prepared by the preparation method of the pinocembrin is high, so that the application quality of the pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.
Drawings
Fig. 1 is a flowchart of application of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, which is provided by the embodiment of the invention.
Fig. 2 is a flowchart of a preparation method of pinocembrin according to an embodiment of the present invention.
Fig. 3 is a flowchart of a preparation method of tanshinol according to an embodiment of the present invention.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
As shown in fig. 1, the invention provides an application method of pinocembrin in preparation of a preparation for preventing cerebral ischemic injury, which comprises the following steps:
S101, weighing 10 parts of pinocembrin, 6 parts of salvianic acid A, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root and 3 parts of bitter orange according to parts by weight;
the peach kernel treatment method comprises the following steps:
Soaking semen Persicae in boiled water, wherein the soaking time is 1-2 hr;
Soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and sterilizing by steaming semen Persicae under high pressure;
S102, mixing and crushing red paeony root, szechuan lovage rhizome, chinese angelica, safflower, peach seed, chrysanthemum, indian buead, twotooth achyranthes root and bitter orange into powder, and then mixing with pinocembrin and danshensu to prepare the preparation for preventing cerebral ischemic injury.
As shown in fig. 2, the preparation method of pinocembrin provided by the invention comprises the following steps:
S201, extracting propolis with purified water and edible alcohol according to different proportions, mixing filtrates after solid-liquid separation, and adjusting the content of effective components to standard requirements to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
S202, adding 96% ethanol into the concentrated solution until the ethanol content is about 75%, standing overnight, and concentrating the supernatant to obtain an extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
S203, semi-preparative high performance liquid chromatography separation and purification of the sample: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
The heating extraction time provided by the invention is 3 hours.
The extraction times provided by the invention are 7 times.
The distilled water consumption is 11 times of the distilled water consumption during heating extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
As shown in FIG 3, the preparation method of the salvianic acid A provided by the invention comprises the following steps:
S301, slicing the red sage root medicinal material, and extracting by adopting an alkaline aqueous solution hot dipping method with the pH value of 7 at 86 ℃ to obtain an extract containing tanshinol; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
s302, loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, continuing eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
The alkaline water used for extraction provided by the invention is sodium hydroxide, potassium hydroxide or ammonia water.
The hot dipping method provided by the invention has the extraction times of 5 times, the dosage of alkaline water is 17 times of the weight of the salvia miltiorrhiza medicinal material, and the extraction time of each time is 3 hours.
The acid provided by the invention is hydrochloric acid, acetic acid or sulfuric acid.
The ethanol provided by the invention is absolute ethanol or 95% ethanol.
The pinocembrin prepared by the preparation method of pinocembrin has high purity, so that the application quality of pinocembrin in preparation of preparations for preventing cerebral ischemic injury is greatly improved; meanwhile, the quality of the salvianic acid A prepared by the salvianic acid A preparation method is high, so that the quality of the application of the brevifolin in preparing the preparation for preventing cerebral ischemic injury is greatly improved.
Four practical application cases of the embodiment of the invention are as follows:
embodiment one: preparation of pharmaceutical formulations
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to the weight parts.
Soaking semen Persicae in boiled water containing appropriate amount of edible salt for 1-2 hr, soaking in hot water for 50 min, peeling, soaking semen Persicae in salt water for half an hour to whiten, and oven drying at low temperature.
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii respectively into powder.
Finally, all the raw materials are mixed to prepare the preparation for preventing cerebral ischemic injury.
Embodiment two: preventing and treating senile people suffering from hypertension for a long time
The patient is given the appropriate amount of the formulation according to the order twice daily. Patients need to monitor blood pressure regularly throughout the course of treatment, taking care of changes in diet and lifestyle. After 3 months of preventive use, the blood pressure of the patient is stable, and symptoms such as dizziness and headache are obviously improved.
Embodiment III: post-operative cerebral ischemic injury prevention
For patients who are about to undergo large-scale surgery, the preparation is administered before the surgery for preventive treatment, and the preparation is continuously used after the surgery to strengthen the protection of cerebral ischemic injury. The recovery status of the patient is continuously observed, and the dosage and the frequency of the drug use are adjusted.
The foregoing is merely illustrative of specific embodiments of the present invention, and the scope of the invention is not limited thereto, but any modifications, equivalents, improvements and alternatives falling within the spirit and principles of the present invention will be apparent to those skilled in the art within the scope of the present invention.

Claims (10)

1. Use of pinocembrin in the preparation of a formulation for preventing cerebral ischemic injury comprising:
Weighing 10 parts of pinocembrin, 6 parts of danshensu, 3 parts of red paeony root, 5 parts of szechuan lovage rhizome, 7 parts of Chinese angelica, 8 parts of safflower, 3 parts of peach seed, 7 parts of chrysanthemum, 6 parts of Indian buead, 4 parts of twotooth achyranthes root, 3 parts of bitter orange and 2 parts of phosphatidylcholine according to parts by weight;
Soaking peach kernels in boiled water, and soaking for 1 to 2 hours with a small amount of edible salt; soaking semen Persicae in hot water for 50 min, removing skin of semen Persicae, soaking semen Persicae in saline water for half an hour to whiten semen Persicae, and oven drying at low temperature;
Pulverizing radix Paeoniae Rubra, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, carthami flos, flos Chrysanthemi, poria, achyranthis radix, and fructus Aurantii separately, and adjusting the pulverizing granularity;
and thirdly, mixing the processed peach kernels, red paeony root, szechuan lovage rhizome, chinese angelica, safflower, chrysanthemum, indian buead, twotooth achyranthes root, bitter orange, pinocembrin, danshensu and a newly added neuroprotectant to prepare the preparation for preventing cerebral ischemic injury.
2. Use of pinocembrin according to claim 1 for the preparation of a formulation for preventing cerebral ischemic injury, wherein the low temperature drying removes water from the material under low temperature and reduced pressure conditions:
Pumping air in the device by using a vacuum pump, creating a vacuum environment in the drying device, wherein water molecules in the substance are easier to evaporate due to the pressure reduction; in the whole process, a certain amount of heat is continuously supplied to the substance, and the heat is transmitted to the substance by radiation and convection from a heating system of the equipment; the moisture will change from liquid to gas after obtaining enough heat and then be separated from the substance; the separated water vapor is pumped by a vacuum pump.
3. Use of pinocembrin according to claim 1 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the pinocembrin is prepared by the following method:
(1) Extracting propolis with purified water and edible alcohol at different ratio, separating solid from liquid, mixing filtrates, and regulating the content of effective components to standard requirement to obtain qualified water-soluble propolis extract; freezing propolis, pulverizing, extracting with distilled water under heating, filtering, naturally cooling the water extractive solution to room temperature, removing the upper coagulated Cera flava, and concentrating the lower aqueous solution under reduced pressure to relative density of about 1.2;
(2) Adding 96% ethanol to the concentrated solution until the ethanol content is about 75%, standing overnight, collecting supernatant, and concentrating to obtain extract; coarse separation of macroporous adsorption resin: dissolving the extract with appropriate amount of water, loading onto macroporous adsorbent resin column, eluting with water, and sequentially eluting with 25%, 45%, 65%, 85%, 96% ethanol-water solution as mobile phase gradient; collecting 45% and 65% ethanol eluting parts respectively, and concentrating to obtain a sample;
(3) Semi-preparative high performance liquid chromatography separation and purification of samples: separating and purifying the sample by semi-preparative high performance liquid chromatography, wherein the chromatographic column is C18SMB100 column, the mobile phase is methanol-water, and the ratio of 50:50, V/V, detecting the wavelength to be 280nm, collecting the fraction of the target component, and concentrating the obtained fraction under reduced pressure to obtain the monomer compounds 3, 4-dimethoxy cinnamic acid and pinocembrin to be separated.
4. Use of pinocembrin according to claim 3 for the preparation of a formulation for the prevention of cerebral ischemic injury, wherein the heat extraction time is 3 hours;
The number of extraction times was 7.
5. The use of pinocembrin according to claim 3 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the distilled water is used in an amount of 11 times during the heat extraction;
the separation and purification are performed by using methanol-water eluent, wherein the elution modes comprise methanol-water gradient elution, 55% methanol-water isocratic elution, 50% methanol-water isocratic elution and 45% methanol-water isocratic elution.
6. The use of pinocembrin according to claim 1 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the preparation method of pinocembrin comprises the following steps:
1) Slicing Saviae Miltiorrhizae radix, and extracting with alkaline water solution with pH of 7 at 86 deg.C to obtain extract containing salvianic acid A; adjusting pH of the extractive solution to 5 with acid, and filtering to remove precipitate; concentrating the supernatant at 66 ℃; precipitating the concentrated solution with ethanol to reach ethanol concentration of 87%, standing, removing precipitate, and concentrating the filtrate at 76deg.C until no ethanol smell;
2) Loading the concentrated solution on a macroporous adsorption resin column, eluting with water with the volume of 5 times of the resin volume, discarding, eluting with water with the volume of 6 times of the resin volume, and collecting the eluent; concentrating the eluent at 78 ℃, regulating the pH to 8 by alkaline water, and freeze-drying to obtain solid; dissolving the above solid with ethanol under heating, filtering, cooling, concentrating the filtrate at low temperature to small volume, and crystallizing to obtain high purity salvianic acid A with content of more than 93%.
7. The use of pinocembrin according to claim 6 for the preparation of a preparation for preventing cerebral ischemic injury, wherein the alkaline water used for the extraction is sodium hydroxide, potassium hydroxide or ammonia water.
8. The use of pinocembrin according to claim 6 for preparing preparation for preventing cerebral ischemic injury, wherein the extraction times by hot dipping method is 5 times, the alkaline water amount is 17 times of the weight of the radix Salviae Miltiorrhizae, and the extraction time is 3 hours each time.
9. Use of pinocembrin according to claim 6 for the preparation of a formulation for the prevention of cerebral ischemic injury, wherein the acid is hydrochloric acid, acetic acid or sulfuric acid.
10. The use of pinocembrin according to claim 6 for the preparation of a formulation for preventing cerebral ischemic injury, wherein the ethanol is absolute ethanol or 95% ethanol.
CN202311772251.7A 2023-12-21 2023-12-21 Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury Pending CN117942367A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311772251.7A CN117942367A (en) 2023-12-21 2023-12-21 Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311772251.7A CN117942367A (en) 2023-12-21 2023-12-21 Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury

Publications (1)

Publication Number Publication Date
CN117942367A true CN117942367A (en) 2024-04-30

Family

ID=90795612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311772251.7A Pending CN117942367A (en) 2023-12-21 2023-12-21 Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury

Country Status (1)

Country Link
CN (1) CN117942367A (en)

Similar Documents

Publication Publication Date Title
CN112870236B (en) Flavone effective part of abelmoschus manihot and preparation method and application thereof
AU2003242135A1 (en) Preparation Method of Danshentotalphenolic Acid and the Use Thereof
CN102119964A (en) Extract of preventing and treating coronary heart disease and stenocardia and preparation method and application thereof
Wu et al. Preparation of paeoniflorin from the stems and leaves of Paeonia lactiflora Pall.‘Zhongjiang’through green efficient microwave-assisted extraction and subcritical water extraction
CN1927293A (en) Chinese medicine composition for treating skin burn and scald
CN106432385A (en) Preparation method for high-purity breviscapine extract as well as preparations and application thereof
CN117942367A (en) Application of pinocembrin in preparation of preparation for preventing cerebral ischemic injury
CN112107639B (en) Application of fructus viticis extract in preparation of antidepressant drugs
CN109172637B (en) Preparation method of capsule for treating rheumatism
CN1712060A (en) Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease
CN1256134C (en) Medicinal composition for treating rheumatoid
CN104116753B (en) The application of aucubin in preparation treatment idiopathic pulmonary fibrosis medicine
CN102895386B (en) Method for performing extraction on angelica dahurica, common cnidium fruit, Chinese red pepper and elecampane inula root and pharmaceutical application
CN112546085A (en) Sambucus chinensis extract for treating gout and preparation method thereof
CN1899574A (en) Chinese medicine composition for preventing and controlling liver cancer and its use
CN1319546C (en) Delayed-releasing preparation for treating osteoporosis
CN115364179B (en) Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof
CN114028526B (en) A pharmaceutical composition for treating gastric precancerous lesion and gastric cancer, and its preparation method
CN111759891B (en) Pharmaceutical composition for treating myocardial ischemia and application thereof
CN114748440B (en) Astragalus glue capsule composition for increasing white and its preparing method and use
CN107582747B (en) Preparation method of Jinma Gantai preparation
CN1123683A (en) Series products of radix notoginseng and cortex eucommiae and their productions
CN1876128A (en) A medicine for treating metrorrhagia and preparation process thereof
CN1283303C (en) Medicine composition for ischemia apoplexy
CN117503856A (en) Application of plant essential oil in preparation of medicine or health product for treating hepatitis B

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication